A randomized, double-blind, placebo-controlled, Phase 1/2a trial protocol to assess the safety and efficacy of TAK-101 administered by microneedles in patients with celiac disease. PPCR [Internet]. 2022 Dec. 21 [cited 2024 Nov. 21];8(3):37-48. Available from: https://journal.ppcr.org/index.php/ppcrjournal/article/view/185